March 9th, 2013
ACC.13 Headquarters
CardioExchange Editors, Staff
CardioExchange is dedicated to bringing you the latest from ACC.13. Check out our coverage below ─ and some of the great debates these posts have sparked ─ then tell us what you think!
News:
- Following an Embargo Break PREVAIL Trial Won’t be Presented at ACC
- HPS2-THRIVE: A ‘Disappointing But Clear’ Result
- Cangrelor During PCI May Reduce Ischemic Events
- Fibrinolysis May Benefit Late-Arriving STEMI Patients
- Eplerenone May Prevent Heart Failure in Acute STEMI Patients
- Another Negative Trial of Darbepoetin Alfa
- Was Atherosclerosis the Real Curse of the Mummy?
- Two Trials Explore On-Pump Versus Off-Pump Bypass Surgery
Analysis:
Follow our Fellows:
- The Real World Intrudes on the Start of the Meeting
- A Fellow Reflects on the Program and on her Progress from Observer to Educator
- Data Sources for Young Investigators
- New Approaches to LDL Lowering
- Great Venue, Great Sessions, but Disappointments Too
- Thinking About What Comes After Fellowship
- The Real Question About Reducing Hospital Readmissions
- You Are My Sunshine
- Learning to Network
NEJM — Recent Cardiology Articles- Intention to Treat — Season 2: The Race Equation: BiDil — The Story of the Black Pill — ITT Episode 2.5 June 4, 2026How did a drug for congestive heart failure get approved and marketed for Black people only?
- Left Atrial Appendage Closure — Should Recommendations Be Expanded? June 4, 2026Owing to the fact that most thromboembolic complications that are attributed to atrial fibrillation originate in the left atrial appendage,1 therapies targeting the anatomical structure that might spare systemic harms are theoretically attractive. Randomized trials of left atrial appendage closure previously garnered an American College of Cardiology–American Heart...
- Left Atrial Appendage Closure or Anticoagulation for Atrial Fibrillation June 4, 2026In patients with atrial fibrillation, left atrial appendage closure was noninferior to NOACs in an analysis of death from cardiovascular causes, stroke, or systemic embolism and was superior for non–procedure-related bleeding.
- Emerging Era for Polymyalgia Rheumatica and GCA — Interleukin-17A Targeting June 3, 2026Since Dr. Phillip Hench reported on the efficacy of glucocorticoids for rheumatoid arthritis in 1949, glucocorticoids have saved many lives and have offered relief to countless patients. Glucocorticoids have been used as the mainstay of treatment for many immune-mediated inflammatory diseases, including polymyalgia rheumatica and giant-cell arteritis (GCA), owing to...
- Science behind the Study: Remuscularizing the Failing Human Heart May 28, 2026The author describes the scientific foundations of a phase 1–2 study of stem-cell–derived ventricular assist tissue transplanted onto the epicardial surface of failing human hearts.
- Intention to Treat — Season 2: The Race Equation: BiDil — The Story of the Black Pill — ITT Episode 2.5 June 4, 2026